[Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer].
The authors are reporting the clinical importance of prostate specific antigen. They concluded that there are false positive and false negative cases. The prostate specific antigen is high in prostatic hyperplasia therefore the distinction between the two disease is impossible on basis of the prostate specific antigen. Prostate specific antigen shows the metastatic cases better [correction of worse] than prostatic acid phosphatase. But prostate specific antigen detects the changes of the clinical course of the disease well and shows the progression sooner. The authors have concluded that prostate specific antigen can not replace phosphatases and bone-scanning in the diagnosis and follow up of patients with prostate carcinoma.